The post Telegram Sells $450M In Toncoin As Token Plunges: Report appeared on BitcoinEthereumNews.com. Update (Jan. 6, 1:20 pm UTC): This article has been updatedThe post Telegram Sells $450M In Toncoin As Token Plunges: Report appeared on BitcoinEthereumNews.com. Update (Jan. 6, 1:20 pm UTC): This article has been updated

Telegram Sells $450M In Toncoin As Token Plunges: Report

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Update (Jan. 6, 1:20 pm UTC): This article has been updated with a statement from Telegram.

Cryptocurrency-friendly messenger Telegram boosted its operating revenue in 2025 as it explores a potential initial public offering (IPO).

Telegram’s revenues hit $870 million in the first half of 2025, up 65% from $525 million a year earlier, the Financial Times reported on Tuesday, citing unaudited financial statements.

About a third of that, or $300 million, came from “exclusivity agreements,” linked to earnings related to Telegram-connected cryptocurrency Toncoin (TON).

The report also said that $500 million of Telegram’s bonds have been frozen in Russia’s central securities depository due to Western sanctions, the FT said, citing anonymous sources.

Telegram reportedly sells $450 million in TON

Telegram posted a net loss of more than $220 million in H1 2025, compared with a $334 net profit in the first half of the previous year. The company targets $2 billion in revenue in 2025.

The loss reportedly came from Telegram having to write down the value of its holdings in Toncoin, which lost 69% of its value in 2025, according to CoinGecko.

Toncoin (TON) price chart in 2025. Source: CoinGecko

“The company told investors it had sold more than $450 million in Toncoin in the year to date,” the report said.

By publishing time, the amount would account for about 10% of TON’s market capitalization of $4.6 billion, according to CoinGecko data.

Telegram denies exposure to Russia

Addressing the bond freeze in Russia, a spokesperson for Telegram said that $500 million figure refers to a bond issue from 2021. The representative noted that Telegram’s latest bond offering in 2025 excluded participation by Russian investors.

“Telegram is not dependent on Russia or Russian capital and does not face bond-related issues due to sanctions,” the spokesperson said, adding:

Telegram launched several bond offerings in recent years, including a $1.7 billion convertible bond offering issued in May 2025. The sale reportedly featured existing backers, including investment giant BlackRock and Abu Dhabi’s investment firm Mubadala.

According to FT sources, Telegram bought back most of the bonds maturing in 2026.

Related: ‘Mixed year for IPOs’ as crypto pulls down US IPO performance

The report comes amid Telegram CEO Pavel Durov remaining under formal investigation in France over the platform’s alleged failure to address criminality, including child abuse content.

In a recent call with some bondholders, Telegram reportedly said it continued to cooperate with authorities regarding Durov’s case and that it needed more resolution before the company could proceed with a public market listing.

Cointelegraph also sought comment from Telegram on its 2025 financials and TON holdings, but the company did not address either in its response.

Magazine: How crypto laws changed in 2025 — and how they’ll change in 2026

Source: https://cointelegraph.com/news/telegram-revenue-2-billion-full-year-target-report?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Market Opportunity
TokenFi Logo
TokenFi Price(TOKEN)
$0.00288
$0.00288$0.00288
-0.89%
USD
TokenFi (TOKEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09